Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma

(2011) J S Liles et al.   BRITISH JOURNAL OF CANCER

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

(2011) Vanja Vaccaro et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pancreatic cancer stem cell biology and its therapeutic implications

(2011) Filip Bednar et al.   JOURNAL OF GASTROENTEROLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts

(2009) C. Larbouret et al.   ANNALS OF ONCOLOGY

Aktuelles zur ErbB2-Diagnostik beim Mammakarzinom

(2009) J. Rüschoff et al.   PATHOLOGE

EGFR and HER2 expression in advanced biliary tract cancer

(2009) Jan Harder et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

(2008) Volker Heinemann et al.   BMC CANCER